查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1928632

宠物抗感染药物市场依药物类别、动物种类、给药途径及通路划分，全球预测，2026-2032年

Pets Anti-infective Drugs Market by Drug Class, Animal Type, Route Of Administration, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，宠物抗感染药物市场价值将达到 10.4 亿美元，到 2026 年将成长到 11 亿美元，到 2032 年将达到 16.5 亿美元，年复合成长率为 6.74%。

关键市场统计数据
基准年 2025 10.4亿美元
预计年份：2026年 11亿美元
预测年份 2032 16.5亿美元
复合年增长率 (%) 6.74%

全面检视不断演变的兽用抗感染药物市场格局，阐述将影响未来策略选择的临床、商业性和监管动态。

宠物抗感染药物市场格局瞬息万变，製造商、经销商、兽医和机构采购商都需要清晰的策略方向。监管力度的加强、诊断和治疗技术的创新以及分销模式的转变，共同重塑了伴侣动物感染疾病的预防、诊断和治疗方式。本文旨在为全面检验推动变革的因素、企业必须应对的策略转折点以及将决定其未来几年领导地位的营运应对措施奠定基础。

深入分析临床、数位化、供应链和监管变革如何融合，从而重新定义兽医学中的抗感染策略和竞争地位。

兽用抗感染领域正经历一系列变革，这些变革正在重新定义竞争优势和临床实践。其中最重要的是，抗菌药物管理已发展成为一项临床要务和商业性预期。抗菌药物管理计画正在影响处方行为、产品标籤考量以及对诊断的重视，从而减少经验性治疗。同时，精准医疗和诊断与治疗的整合程度显着提高，照护现场分子检测和快速药敏试验越来越多地用于指导治疗决策，并缩短启动适当治疗的时间。

对近期关税变化如何改变整个价值链的供应链经济、筹资策略、製造本地化和分销方式进行实际评估。

美国2025年实施的新关税已对兽用抗感染药物价值链造成了实质的衝击，影响了采购、生产经济效益和筹资策略。关税调整提高了某些进口活性药物成分和製剂的到岸成本，迫使生产商和经销商重新评估其供应商合约和定价框架。为此，采购团队正在加快供应商多元化，并探索其他原材料采购地，以缓解利润压力并维持产品供应。

一个综合细分框架，解释了药物类别、动物种类、通路和给药途径如何共同影响研发重点和商业化策略。

细分市场洞察揭示了驱动产品类别、动物种类、通路和给药方式等多层次需求模式和策略重点的动态因素。依药物类别划分，市场结构涵盖抗生素、抗真菌药物、抗寄生虫药和抗病毒药，其中抗生素进一步细分为Aminoglycosides、β-内酰胺类、大环内酯类和四环霉素。抗真菌药物主要包括Azole和Polyenes，抗寄生虫药以球虫和内分泌苷类药物为主，抗病毒药则以核苷类似物为主。这些区分至关重要，因为不同类别的药物在治疗特性、合理使用方案和监管预期方面存在显着差异，从而影响研究重点和商业化策略。

区域差异化的叙述表明，不同的法规结构、临床规范、供应链和数位化应用如何影响世界各地抗感染药物的取得和商业化。

兽用抗感染药物领域的区域趋势反映了美洲、欧洲、中东和非洲以及亚太地区不同的法规环境、临床实践和商业性准入模式。在美洲，临床医生网路和饲主的期望推动了对便利製剂和快速诊断的需求，而供应链的韧性和监管机构之间的合作则影响产品的供应和上市后监测。放眼东方，欧洲、中东和非洲拥有多种监管标准和管理方案，协调统一的努力和跨境贸易政策在药物核准和分销方面发挥关键作用。

对竞争行动和企业趋势进行策略评估，优先考虑差异化配方、诊断整合以及伙伴关係关係为主导的产业成长。

兽用抗感染药物领域的竞争格局正因策略联盟、定向收购以及对差异化製剂和诊断技术的重点投资而重塑。掌握老牌製药公司继续利用规模经济、监管专业知识和广泛的分销网络，但专业的兽药公司和生物技术Start-Ups正在推动小众适应症、新型给药机制以及诊断和治疗整合方面的创新。对于那些寻求控製成本并加快临床应用进程的公司而言，契约製造组织 (CMO) 和专业经销商正成为日益重要的合作伙伴。

提供切实可行、影响深远的策略指南，以增强韧性、促进管理并建立符合不断变化的临床和监管预期的商业模式

在不断变化的抗感染剂市场中，产业领导者应采取一系列切实可行的倡议，以增强市场韧性、提升临床疗效并维持商业性竞争力。首先，将产品系列与药物管理原则相契合，并投资于诊断辅助应用案例，可以减少不合理处方，并为临床医生创造清晰的价值提案。其次，企业应实现采购多元化，对多家关键原料供应商合格，并评估有针对性的本土化或近岸外包，以降低海关和物流风险。

报告清晰地阐述了一种多方面的研究途径，该方法结合了定性洞察、定量检验和供应链图谱分析，以得出可操作的结论。

本分析的调查方法结合了结构化、多维度的研究途径，以确保研究的深度、多角度验证和相关性。主要研究包括对临床医生、采购人员、监管事务专家和分销主管进行深入访谈，以收集关于处方行为、供应链限制因素和分销管道趋势的第一手资料。次要研究包括对同行评审文献、监管指导文件、专利申请和已发布的临床指南进行严格的审查，以检验临床趋势和药物管理框架。

为确保在兽医抗感染领域保持长期领先地位，必须明确整合策略问题和临床重点，并将其转化为跨部门行动。

总之，兽用抗感染药物生态系统正处于转折点，临床管理、诊断创新和供应链韧性将共同决定策略成败。优先考虑以诊断为导向的治疗方案、使产品设计与实际用药需求相匹配并投资于采购多元化的利益相关人员，将更有能力在应对贸易逆风的同时，提供稳定的临床疗效。分销模式也在发生变化，优化通路组合併整合数位互动的企业，将能够为更广泛的患者群体带来更高的药物可及性和依从性。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 宠物抗感染药物市场（依药物类别划分）

  • 抗生素
    • Aminoglycosides
    • β-内酰胺类
    • 大环内酯类
    • 四环霉素
  • 抗真菌药物
    • Azole
    • Polyenes
  • 抗寄生虫药物
    • 球虫药
    • 内皮苷
  • 抗病毒药物

9. 依动物种类分類的宠物抗感染药物市场

  • 猫
  • 狗
  • 马
  • 小型哺乳动物
    • 兔子
    • 囓齿动物

10. 宠物抗感染药物市场（依给药途径划分）

  • 口服
  • 肠外给药
    • 肌肉内注射
    • 静脉注射
    • 皮下注射
  • 外用

第十一章：宠物抗感染药物市场（依通路划分）

  • 线上零售商
  • 零售药房
  • 兽医诊所
  • 兽药

第十二章：宠物抗感染药物市场区域分析

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：宠物抗感染药物市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：各国宠物抗感染药物市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国：宠物抗感染药物市场

16. 中国：宠物抗感染药物市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Bayer Animal Health
  • Bimeda Animal Health
  • Boehringer Ingelheim Animal Health
  • Cargill Inc.
  • Ceva Sante Animale
  • China Animal Healthcare Ltd.
  • China Animal Husbandry Industry Corporation
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Evonik Industries AG
  • Guangdong Wens Dahuanong Biotechnology Co. Ltd.
  • Hester Biosciences Ltd.
  • Huvepharma
  • IDEXX Laboratories, Inc.
  • Intas Pharmaceuticals
  • Kyoritsu Seiyaku Corporation
  • Merck Animal Health
  • Nippon Zenyaku Kogyo Co., Ltd.
  • Norbrook Laboratories
  • Nutreco NV
  • Phibro Animal Health Corporation
  • Prodivet Pharmaceuticals SA/NV
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-92740D85F07D

The Pets Anti-infective Drugs Market was valued at USD 1.04 billion in 2025 and is projected to grow to USD 1.10 billion in 2026, with a CAGR of 6.74%, reaching USD 1.65 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.04 billion
Estimated Year [2026] USD 1.10 billion
Forecast Year [2032] USD 1.65 billion
CAGR (%) 6.74%

A comprehensive orientation to the evolving veterinary anti-infective landscape that frames clinical, commercial, and regulatory dynamics shaping future strategic choices

The pets anti-infective landscape is evolving at a pace that demands strategic clarity from manufacturers, distributors, veterinarians, and institutional purchasers. Increasing regulatory scrutiny, innovations in diagnostics and therapeutics, and shifting distribution models are converging to reshape how infectious diseases in companion animals are prevented, diagnosed, and treated. This introduction sets the stage for a comprehensive examination of the forces that are driving change, the strategic inflection points organizations must navigate, and the operational responses that will define leadership in the coming years.

Within veterinary care, the interplay between clinical practice, pharmaceutical innovation, and owner expectations has become more pronounced. Clinicians are adopting rapid diagnostic tools to guide therapy decisions, while pet owners are more informed and engaged in treatment choices. At the same time, manufacturers face pressures to demonstrate safety, efficacy, and responsible stewardship, particularly as antimicrobial resistance becomes a pressing concern. Transitional dynamics such as e-commerce growth, telemedicine adoption, and expanded roles for specialty pharmacies further complicate traditional pathways to care. In response, industry stakeholders are recalibrating product development priorities, supply chain approaches, and market access strategies to align with a changing clinical and commercial environment.

As this report unfolds, readers will find a structured exploration of transformative shifts, policy impacts, segmentation insights, regional dynamics, competitive behaviors, and actionable recommendations designed to help organizations convert intelligence into operational advantage and long-term resilience

An in-depth analysis of the converging clinical, digital, supply chain, and regulatory transformations that are redefining veterinary anti-infective strategies and competitive positioning

The veterinary anti-infective sector is experiencing a series of transformative shifts that are redefining competitive advantage and clinical practice. Foremost among these is the maturation of antimicrobial stewardship as both a clinical imperative and a commercial expectation; stewardship programs are influencing prescribing behaviors, product labeling considerations, and the emphasis on diagnostics to reduce empiric therapy. At the same time, there is a pronounced shift toward precision therapeutics and improved diagnostic-therapy integration, with point-of-care molecular assays and rapid susceptibility testing increasingly informing treatment decisions and shortening time-to-appropriate therapy.

Concurrently, digital channels are altering access and adherence dynamics. Telemedicine consultations and e-commerce platforms are extending the reach of veterinary services and creating new pathways for product distribution, while data-driven adherence tools and remote monitoring are supporting better clinical outcomes. Supply chain resilience and localization of active pharmaceutical ingredient sourcing are gaining prominence, prompting manufacturers to reassess sourcing strategies and invest in alternative supplier relationships. Moreover, regulatory evolution is influencing product registration timelines, post-market surveillance obligations, and labeling for responsible use, driving closer collaboration between regulatory affairs and commercial teams.

Finally, shifting animal demographics, including higher rates of pet ownership and expanded care for horses and small mammals, are broadening the patient population and altering product demand characteristics. Together, these shifts create both challenges and opportunities: organizations that align product portfolios, commercialization models, and stewardship commitments with these trends will be best positioned to lead clinical practice and capture long-term value

A practical assessment of how recent tariff changes have altered supply chain economics, sourcing strategies, manufacturing localization, and distribution approaches across the value chain

The implementation of new tariffs by the United States in 2025 has introduced tangible perturbations across the veterinary anti-infective value chain, affecting procurement, production economics, and sourcing strategies. Tariff adjustments have increased landed costs for certain imported active pharmaceutical ingredients and finished dosage forms, which in turn have prompted both manufacturers and distributors to reexamine vendor contracts and pricing frameworks. In response, procurement teams have accelerated supplier diversification efforts and explored alternative geographies for raw material sourcing to mitigate margin pressure and maintain product availability.

Moreover, tariffs have catalyzed discussions around onshoring and nearshoring of key manufacturing steps, particularly for critical intermediates where supply continuity is paramount. As a result, some organizations are reallocating capital to enhance domestic manufacturing capacity or to qualify additional contract manufacturing partners within tariff-favored jurisdictions. Transitional logistics effects have also emerged: increased customs complexity and shifts in lead times have required more proactive inventory planning and dynamic safety stock strategies to avoid clinical shortages.

In parallel, tariff-driven cost pressures have spilled over into distribution economics, incentivizing channel optimization and exploration of lower-cost fulfillment models. For some stakeholders, the tariffs have accelerated strategic partnerships with local distributors and veterinary pharmacy networks to preserve price competitiveness. Importantly, regulatory harmonization and free-trade negotiations remain key levers that could moderate these impacts over time, and organizations that combine tactical supply chain adjustments with strategic engagement in trade policy discussions are better equipped to navigate the evolving trade environment

An integrated segmentation framework explaining how drug class, animal type, distribution channels, and administration routes jointly influence development priorities and commercialization tactics

Segmentation insights reveal layered dynamics that drive demand patterns and strategic priorities across product classes, animal types, distribution routes, and administration modes. Based on drug class, the landscape spans antibiotics, antifungals, antiparasitics, and antivirals, with antibiotics further differentiated into aminoglycosides, beta-lactams, macrolides, and tetracyclines; antifungals are primarily represented by azoles and polyenes, antiparasitics are defined by anticoccidials and endectocides, and antivirals are centered on nucleoside analogues. These distinctions matter because therapeutic characteristics, stewardship implications, and regulatory expectations vary substantially by class, thereby shaping research priorities and commercialization strategies.

Considering animal type, demand drivers and treatment pathways diverge across cats, dogs, horses, and small mammals, with the latter category further segmented into rabbits and rodents. Each animal type has unique dosing conventions, formulation preferences, and clinical care models, which influence product design and labeling decisions. In addition, distribution channel segmentation highlights the role of online retailers, retail pharmacies, veterinary hospitals, and veterinary pharmacies in shaping access and adherence. Channel selection impacts go-to-market tactics, pricing strategies, and the need for clinician education or consumer-facing support.

Route-of-administration distinctions - oral, parenteral, and topical - further refine commercial approaches, with parenteral forms being subdivided into intramuscular, intravenous, and subcutaneous delivery. These route distinctions affect manufacturing complexity, cold-chain needs, and clinical training requirements. By integrating these segmentation lenses, organizations can better align R&D investment, channel development, and clinical support programs to the specific needs of each patient population and product type

A regionally differentiated narrative showing how regulatory frameworks, clinical norms, supply chains, and digital adoption shape anti-infective access and commercialization across global regions

Regional dynamics in the veterinary anti-infective arena reflect distinct regulatory ecosystems, clinical practices, and commercial access models across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, clinician networks and owner expectations drive demand for convenience-oriented formulations and rapid diagnostics, while supply chain resilience and regulatory collaborations influence product availability and post-market surveillance. Moving eastward, Europe, Middle East & Africa presents a mosaic of regulatory standards and stewardship programs, where harmonization efforts and cross-border trade policies play pivotal roles in shaping approvals and distribution.

Asia-Pacific features rapid modernization of veterinary services, growing pet ownership, and a rising appetite for specialty therapeutics, which together create opportunities for product differentiation and localized manufacturing partnerships. Across all regions, regional public health priorities and trade agreements inform strategic sourcing and import strategies, and stakeholders must adapt commercialization approaches to local clinical norms and reimbursement structures. Transitional considerations such as regional supply chain bottlenecks, varying rates of digital adoption, and local enforcement of antimicrobial stewardship guidelines require nuanced go-to-market playbooks.

Consequently, companies that tailor regulatory engagement, distribution partnerships, and clinician education to the specific dynamics of each region will be better positioned to achieve operational continuity and clinical impact. Cross-regional learning also creates opportunities: practices and technologies validated in one region can be adapted to accelerate adoption elsewhere, provided that localization of clinical evidence and regulatory dossiers is managed proactively

A strategic appraisal of competitive behaviors and corporate moves that are privileging differentiated formulations, diagnostics integration, and partnership-driven growth across the industry

Competitive dynamics among companies active in veterinary anti-infectives are being reshaped by strategic partnerships, targeted acquisitions, and focused investment in differentiated formulations and diagnostics. Established pharmaceutical manufacturers continue to leverage scale, regulatory expertise, and broad distribution relationships, while specialized veterinary firms and biotech startups are driving innovation in niche indications, novel delivery mechanisms, and diagnostic-therapeutic integration. Contract manufacturing organizations and specialized distributors are increasingly critical partners for firms seeking to control costs and accelerate time-to-clinic.

Moreover, companies are bifurcating strategies between branded innovation and generic provision, with some organizations prioritizing premium, stewardship-aligned products for acute clinical scenarios and others focusing on cost-effective generics to serve routine treatment needs. Research and development investments are being channeled into formulations that improve compliance, such as long-acting injectables and palatable oral forms, as well as into companion diagnostics that support targeted therapy. Strategic alliances between diagnostic providers and drug developers are becoming more common, enabling co-development of diagnostic-guided treatment pathways.

In the commercial arena, firms that integrate robust field support for veterinarians, digital engagement tools for pet owners, and sophisticated channel management capabilities are gaining traction. Additionally, companies that proactively engage with regulatory authorities and stewardship initiatives to demonstrate responsible use are enhancing their reputational capital and easing market access challenges. Overall, competitive advantage is accruing to organizations that blend scientific differentiation with operational agility and trusted stakeholder relationships

Actionable, high-impact strategic directives designed to enhance resilience, promote stewardship, and align commercial models with evolving clinical and regulatory expectations

Industry leaders should pursue a series of pragmatic actions to strengthen resilience, enhance clinical impact, and preserve commercial competitiveness in the evolving anti-infective landscape. First, aligning product portfolios with stewardship principles and investing in diagnostic-supported use cases will reduce inappropriate prescribing and create clearer value propositions for clinicians. Second, companies should diversify sourcing and qualify multiple suppliers for critical inputs while evaluating targeted onshoring or nearshoring to reduce tariff exposure and logistics risk.

In parallel, investing in channel optimization is essential: firms should deepen partnerships with veterinary hospitals and pharmacies while expanding controlled online distribution models that preserve clinical oversight and adherence. Digital tools that support telemedicine, remote monitoring, and pet owner education can bolster outcomes and drive differentiation. Research and development should prioritize delivery formats that improve compliance and safety, such as palatable oral formulations, long-acting injectables, and topical therapies suited for home administration.

Finally, proactive regulatory engagement and participation in cross-sector stewardship initiatives will help shape favorable policy environments and accelerate acceptance of novel diagnostic-therapeutic combinations. By combining operational resilience with clinical stewardship and strategic channel management, companies can both protect margin and strengthen long-term clinical credibility

A transparent overview of the multi-method research approach that blended qualitative insight, quantitative validation, and supply chain mapping to generate actionable intelligence

The research methodology underpinning this analysis combined a structured, multi-source approach to ensure depth, triangulation, and relevance. Primary research included in-depth interviews with clinical practitioners, procurement leaders, regulatory affairs professionals, and distribution executives to capture first-hand insights into prescribing behaviors, supply chain constraints, and channel dynamics. Secondary research encompassed a rigorous review of peer-reviewed literature, regulatory guidance documents, patent filings, and published clinical guidelines to validate clinical trends and stewardship frameworks.

Quantitative validation was achieved through analysis of industry datasets and transactional proxies to understand distribution patterns and channel shifts, while qualitative synthesis brought context to the behavioral drivers underlying observed trends. Supply chain mapping exercises identified key nodes of vulnerability and potential mitigation levers, and scenario analysis explored the implications of tariff changes and regulatory policy shifts. Throughout the research process, analysts applied critical appraisal to evidence sources and engaged subject-matter experts to test interpretations and refine recommendations.

Limitations of the methodology are acknowledged, including varying data transparency across jurisdictions and the rapidly evolving nature of diagnostic and therapeutic innovation. Nevertheless, the mixed-methods approach ensures that findings are both evidence-based and operationally actionable, providing a reliable foundation for strategic decision-making

A concise synthesis of strategic imperatives and clinical priorities that must be translated into cross-functional actions to secure long-term leadership in veterinary anti-infectives

In conclusion, the veterinary anti-infective ecosystem is at an inflection point where clinical stewardship, diagnostic innovation, and supply chain resilience collectively determine strategic success. Stakeholders who prioritize diagnostic-guided therapy, align product design with real-world administration needs, and invest in diversified sourcing will be better positioned to deliver consistent clinical outcomes while navigating trade-related headwinds. Distribution models are also shifting, and companies that optimize channel mixes and integrate digital engagement will enhance access and adherence for a broader range of patient types.

Competitive advantage will accrue to organizations that pair scientific differentiation with operational agility and proactive regulatory engagement. By embedding stewardship into commercialization strategies and fostering partnerships across diagnostics, manufacturing, and distribution, firms can strengthen trust with clinicians and pet owners while addressing public health concerns related to antimicrobial resistance. Looking ahead, sustained success will depend on the ability to translate insights into concrete actions across R&D, supply chain, and commercial functions, ensuring that innovation reaches patients in a timely, accessible, and responsible manner

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pets Anti-infective Drugs Market, by Drug Class

  • 8.1. Antibiotics
    • 8.1.1. Aminoglycosides
    • 8.1.2. Beta-Lactams
    • 8.1.3. Macrolides
    • 8.1.4. Tetracyclines
  • 8.2. Antifungals
    • 8.2.1. Azoles
    • 8.2.2. Polyenes
  • 8.3. Antiparasitics
    • 8.3.1. Anticoccidials
    • 8.3.2. Endectocides
  • 8.4. Antivirals

9. Pets Anti-infective Drugs Market, by Animal Type

  • 9.1. Cats
  • 9.2. Dogs
  • 9.3. Horses
  • 9.4. Small Mammals
    • 9.4.1. Rabbits
    • 9.4.2. Rodents

10. Pets Anti-infective Drugs Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Parenteral
    • 10.2.1. Intramuscular
    • 10.2.2. Intravenous
    • 10.2.3. Subcutaneous
  • 10.3. Topical

11. Pets Anti-infective Drugs Market, by Distribution Channel

  • 11.1. Online Retailers
  • 11.2. Retail Pharmacies
  • 11.3. Veterinary Hospitals
  • 11.4. Veterinary Pharmacies

12. Pets Anti-infective Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Pets Anti-infective Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Pets Anti-infective Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Pets Anti-infective Drugs Market

16. China Pets Anti-infective Drugs Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Bayer Animal Health
  • 17.6. Bimeda Animal Health
  • 17.7. Boehringer Ingelheim Animal Health
  • 17.8. Cargill Inc.
  • 17.9. Ceva Sante Animale
  • 17.10. China Animal Healthcare Ltd.
  • 17.11. China Animal Husbandry Industry Corporation
  • 17.12. Dechra Pharmaceuticals PLC
  • 17.13. Elanco Animal Health Incorporated
  • 17.14. Evonik Industries AG
  • 17.15. Guangdong Wens Dahuanong Biotechnology Co. Ltd.
  • 17.16. Hester Biosciences Ltd.
  • 17.17. Huvepharma
  • 17.18. IDEXX Laboratories, Inc.
  • 17.19. Intas Pharmaceuticals
  • 17.20. Kyoritsu Seiyaku Corporation
  • 17.21. Merck Animal Health
  • 17.22. Nippon Zenyaku Kogyo Co., Ltd.
  • 17.23. Norbrook Laboratories
  • 17.24. Nutreco N.V.
  • 17.25. Phibro Animal Health Corporation
  • 17.26. Prodivet Pharmaceuticals SA/NV
  • 17.27. Vetoquinol S.A.
  • 17.28. Virbac S.A.
  • 17.29. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES PETS ANTI-INFECTIVE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY BETA-LACTAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY BETA-LACTAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY BETA-LACTAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY AZOLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY AZOLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY POLYENES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY POLYENES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIPARASITICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIPARASITICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIPARASITICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTICOCCIDIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTICOCCIDIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTICOCCIDIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ENDECTOCIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ENDECTOCIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ENDECTOCIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY CATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY CATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY CATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY HORSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY HORSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY HORSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY SMALL MAMMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY SMALL MAMMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY SMALL MAMMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY SMALL MAMMALS, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY RABBITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY RABBITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY RABBITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY RODENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY RODENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY RODENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ONLINE RETAILERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ONLINE RETAILERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ONLINE RETAILERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY VETERINARY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY VETERINARY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY VETERINARY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY SMALL MAMMALS, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY SMALL MAMMALS, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY SMALL MAMMALS, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY SMALL MAMMALS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY SMALL MAMMALS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY SMALL MAMMALS, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY SMALL MAMMALS, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY SMALL MAMMALS, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY SMALL MAMMALS, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. GCC PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. GCC PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 189. GCC PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 190. GCC PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 191. GCC PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 192. GCC PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. GCC PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY SMALL MAMMALS, 2018-2032 (USD MILLION)
  • TABLE 194. GCC PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. GCC PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 196. GCC PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY SMALL MAMMALS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY SMALL MAMMALS, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. G7 PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. G7 PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 219. G7 PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 220. G7 PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 221. G7 PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 222. G7 PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. G7 PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY SMALL MAMMALS, 2018-2032 (USD MILLION)
  • TABLE 224. G7 PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. G7 PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 226. G7 PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. NATO PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. NATO PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 229. NATO PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 230. NATO PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 231. NATO PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 232. NATO PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. NATO PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY SMALL MAMMALS, 2018-2032 (USD MILLION)
  • TABLE 234. NATO PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. NATO PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 236. NATO PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES PETS ANTI-INFECTIVE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY SMALL MAMMALS, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANTIPARASITICS, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY SMALL MAMMALS, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA PETS ANTI-INFECTIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)